Massive Stock Price, News & Analysis

FSD Pharma has appointed Dr. Eleanor N. Fish, an expert in immunology and inflammatory disorders, to its Research and Clinical Advisory Board. Dr. Fish joins the firm to enhance the development of FSD-PEA, an anti-inflammatory agent, and Lucid-MS, aimed at treating multiple sclerosis. Her extensive experience, including her role on the Government of Canada’s Expert Scientific Panel, is expected to drive the company’s research and clinical initiatives forward.

FSD Pharma Inc. (NASDAQ: HUGE) has partnered with Covar Pharmaceuticals Inc. to produce research quantities of its drug candidate, Lucid-PSYCH, for clinical evaluation. This psychoactive compound aims to treat major depressive disorders and is supported by machine learning analysis of its properties. Under the agreement, Covar will manufacture both Non-GMP and GMP versions of Lucid-PSYCH for preclinical and Phase 1 clinical trials. The initiative is part of FSD's strategy to move Lucid-PSYCH from research to clinical application, with expectations of IND approval.

FSD Pharma, a life sciences holding company, announced participation in the KCSA Psychedelics Investor Conference on October 13-14, 2021. Interim CEO Anthony Durkacz and Lucid Psycheceuticals CEO Dr. Lakshmi P. Kotra will present live on October 13 at 2:30 p.m. ET. Investors can register for the event here. FSD Pharma focuses on innovative healthcare solutions and is actively pursuing acquisitions in the biotech space, particularly targeting mental health disorders and neurodegenerative diseases.

FSD Pharma Inc. (NASDAQ: HUGE) has engaged several firms including Hybrid Financial Ltd., North Equities Corp., and Looking Glass Capital Consultants to enhance market awareness and shareholder communication. The contracts involve monthly fees and the issuance of common shares as compensation, totaling approximately US$22,500 to US$50,000 per month. Integral Wealth Securities Limited has also been retained for market-making services to improve liquidity. These efforts signify a strategic allocation of resources toward investor relations following a review of capital on hand.

FSD Pharma Inc. has successfully acquired Lucid Psycheceuticals Inc. for approximately CAD$11.3 million (US$8.9 million) in FSD stock. This acquisition is aimed at enhancing FSD Pharma's portfolio in developing therapies for neurodegenerative diseases and mental health disorders. Dr. Lakshmi P. Kotra will lead Lucid as a wholly-owned subsidiary, focusing on innovative drug development. The acquisition strengthens FSD's pipeline of patent-protected drug candidates and is expected to synergize their anti-inflammatory research efforts.

FSD Pharma (HUGE) announced a definitive agreement to acquire Lucid Psycheceuticals for approximately US$9 million in FSD stock. The acquisition aims to bolster FSD's pipeline in psychedelics and medical cannabis, specifically targeting neurodegenerative diseases and mental health disorders. Lucid brings a strong pipeline of therapeutic compounds and is partnered with the University Health Network for exclusive rights to new chemical entities. The transaction involves the issuance of approximately 4.5 million FSD Shares and requires shareholder approval.

FSD Pharma Inc. (NASDAQ:HUGE) has announced the termination of its Phase 2 clinical trial for FSD-201, designed to treat COVID-19, after an independent review indicated its commercial viability was unlikely. Following the FDA's approval of the IND in June 2020 and the Phase 2 study in September 2020, the company has opted to refocus resources on more viable opportunities. Despite the disappointment over discontinuing the trial, FSD Pharma remains committed to exploring other commercial avenues for FSD-201, as stated by President Zeeshan Saeed.

FSD Pharma Inc. (Nasdaq: HUGE) has terminated CEO Dr. Raza Bokhari for cause following an investigation by a special committee into misconduct, including breaches of court orders and misappropriation of funds. Anthony Durkacz has been appointed as interim CEO, with Zeeshan Saeed reinstated as President. The Company aims to refocus on acquiring biotech assets, auditing its Phase 2 Clinical Trial, and evaluating the commercial viability of its drug compound, FSD201. FSD also plans to improve investor relations.

FSD Pharma Inc. (Nasdaq: HUGE) has appointed Mr. Adnan Bashir as an independent director following Mr. Frank Lavelle's resignation. With over 14 years in strategic management, Bashir's experience includes turning around business operations and implementing new technologies. This appointment fills a Board vacancy and aims to strengthen FSD’s leadership. Additionally, the company announced the grant of stock options to directors and officers, allowing the purchase of 2,170,000 shares at C$2.25, expiring in three years.